|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 146.00 GBX | 0.00% |
|
+0.69% | +14.06% |
| 02/06 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 | |
| 26/05 | Diaceutics PLC Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Diaceutics PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 85.75 | 63.68 | 73.32 | 106.1 | 108.7 | 123.6 | - | - |
| Change | - | -25.74% | 15.14% | 44.67% | 2.47% | 13.74% | - | - |
| Enterprise Value (EV) 1 | 66.08 | 43.84 | 56.65 | 93.32 | 101.3 | 115.9 | 111.5 | 104.7 |
| Change | - | -33.66% | 29.24% | 64.73% | 8.6% | 14.37% | -3.82% | -6.07% |
| P/E | - | 89.9x | -42x | -62.1x | - | - | - | - |
| PBR | - | 1.53x | 1.8x | 2.66x | 2.67x | 3.01x | 2.68x | 2.22x |
| PEG | - | - | 0x | 25.71x | - | - | - | - |
| Capitalization / Revenue | 6.15x | 3.26x | 3.09x | 3.3x | 2.83x | 2.63x | 2.2x | 1.84x |
| EV / Revenue | 4.74x | 2.25x | 2.39x | 2.9x | 2.64x | 2.47x | 1.98x | 1.56x |
| EV / EBITDA | 28.1x | 12.2x | 24x | 22.2x | 13.4x | 11.2x | 8.1x | 5.77x |
| EV / EBIT | 120x | 76.4x | -18.8x | -38x | 57.5x | 36.2x | 21.7x | 11.2x |
| EV / FCF | -13.1x | 194x | -16x | -23.4x | -19.2x | 234x | 16.3x | 10.8x |
| FCF Yield | -7.61% | 0.52% | -6.26% | -4.27% | -5.2% | 0.43% | 6.13% | 9.22% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1 |
| Rate of return | - | - | - | - | - | - | - | 68.5% |
| EPS 2 | - | 0.0084 | -0.0207 | -0.0202 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 47 | 56.31 | 67.06 |
| EBITDA 1 | 2.349 | 3.583 | 2.357 | 4.206 | 7.573 | 10.35 | 13.77 | 18.16 |
| EBIT 1 | 0.55 | 0.574 | -3.018 | -2.455 | 1.761 | 3.2 | 5.149 | 9.381 |
| Net income 1 | 0.561 | 0.724 | -1.746 | -1.703 | 0.097 | -1.1 | 1.5 | 4.3 |
| Net Debt 1 | -19.68 | -19.84 | -16.67 | -12.74 | -7.344 | -7.71 | -12.14 | -18.9 |
| Reference price 2 | 1.020 | 0.755 | 0.870 | 1.255 | 1.280 | 1.460 | 1.460 | 1.460 |
| Nbr of stocks (in thousands) | 84,069 | 84,339 | 84,274 | 84,515 | 84,912 | 84,670 | - | - |
| Announcement Date | 22/03/22 | 17/04/23 | 21/05/24 | 13/05/25 | 26/05/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 2.47x | 11.2x | -.--% | 17Cr | |
| -100.91x | 20.77x | 51.72x | -.--% | 5.52TCr | |
| 37.55x | 2.87x | 22.75x | 1.17% | 417.84Cr | |
| 94.14x | 12.06x | 18.8x | 0.27% | 320.17Cr | |
| -25.31x | - | - | 0.1% | 123.87Cr | |
| 41.48x | 17.11x | 26.56x | 0.56% | 123.2Cr | |
| 26.75x | 3.61x | 14.42x | 0.67% | 122.75Cr | |
| Average | 12.28x | 9.82x | 24.24x | 0.4% | 949.31Cr | |
| Weighted average by Cap. | -76.34x | 18.76x | 46.96x | 0.11% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXRX Stock
- Valuation Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
